S-CELTENSIFY Trademark
Trademark Overview
On Wednesday, October 16, 2024, a trademark application was filed for S-CELTENSIFY with the United States Patent and Trademark Office. The USPTO has given the S-CELTENSIFY trademark a serial number of 79411977. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Monday, August 18, 2025. This trademark is owned by Samsung Biologics Co., Ltd.. The S-CELTENSIFY trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:
Custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; custom manufacture of cell lines for manufacturing biopharmaceuticals; chemical treatment of liquids; processing of medicinal materials; custom manufacture of pharmaceuticals; processing of pharmaceutical preparations; preservation of pharmaceuticals; processing of pharmaceuticals; custom manufacture of specific antibody-binding glycosylated drugs; processing of chemicals.
Scientific laboratory services for high-efficiency glycan analysis; culturing of cells for scientific research purposes; scientific research; biological research and analysis relating to glycosylation profiles; multiple nucleic acid analysis; protein analysis; toxicity analysis; scientific research in the field of molecular analysis; development of biotechnology; biotechnological research; scientific research in the field of biological analysis; biological research; scientific research in the field of biologics; scientific research in the field of biochemical analysis; biochemical research; food research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research on the subject of pharmaceuticals; pharmaceutical product evaluation; clinical research in the field of medicine; testing services for assessing the efficiency of pharmaceuticals; scientif...
General Information
| Serial Number | 79411977 |
| Word Mark | S-CELTENSIFY |
| Filing Date | Wednesday, October 16, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Monday, August 18, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; custom manufacture of cell lines for manufacturing biopharmaceuticals; chemical treatment of liquids; processing of medicinal materials; custom manufacture of pharmaceuticals; processing of pharmaceutical preparations; preservation of pharmaceuticals; processing of pharmaceuticals; custom manufacture of specific antibody-binding glycosylated drugs; processing of chemicals. |
| Description of Mark | The mark consists of the stylized wording "S-Celtensify". |
| Pseudo Mark | S CELTENSIFY |
| Goods and Services | Scientific laboratory services for high-efficiency glycan analysis; culturing of cells for scientific research purposes; scientific research; biological research and analysis relating to glycosylation profiles; multiple nucleic acid analysis; protein analysis; toxicity analysis; scientific research in the field of molecular analysis; development of biotechnology; biotechnological research; scientific research in the field of biological analysis; biological research; scientific research in the field of biologics; scientific research in the field of biochemical analysis; biochemical research; food research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research on the subject of pharmaceuticals; pharmaceutical product evaluation; clinical research in the field of medicine; testing services for assessing the efficiency of pharmaceuticals; scientific research in the field of genetics and genetic engineering; scientific research in the field of genetics; computer programming in the medical field; medical research laboratories; computer project management services relating to imaging medical data; medicine research; analysis and evaluation of medical product development; providing information on the testing, inspection and research of medical products; providing medical and scientific research information in the field of clinical trial progress; scientific research in the nature of conducting clinical trials for others |
Classification Information
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, December 12, 2024 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, December 12, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Samsung Biologics Co., Ltd. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
Trademark Events
| Event Date | Event Description |
| Thursday, December 12, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, December 13, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, December 13, 2024 | APPLICATION FILING RECEIPT MAILED |
| Friday, March 7, 2025 | ASSIGNED TO EXAMINER |
| Tuesday, March 11, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, April 18, 2025 | REFUSAL PROCESSED BY MPU |
| Friday, April 18, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, May 9, 2025 | REFUSAL PROCESSED BY IB |
| Monday, August 18, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, August 18, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, August 18, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, March 12, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
